• The FDA accepted Merck’s application for priority review of sacituzumab tirumotecan for previously treated adults with endometrial cancer.
• The application covers patients previously treated with platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor, separately or in combination.
• The FDA’s target decision date is June 15, 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261026572930) on October 26, 2026, and is solely responsible for the information contained therein.